IRLAB Therapeutics AB (publ) (STO: IRLAB.A)

Market Cap	746.91M
Revenue (ttm)	41.59M
Net Income (ttm)	-119.45M
Shares Out	51.87M
EPS (ttm)	-2.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,109
Open	14.55
Previous Close	14.55
Day's Range	14.15 - 14.70
52-Week Range	5.58 - 20.20
Beta	0.71
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2024

About IRLAB Therapeutics AB

IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson’s disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 research programs for the treatment of neurodegenerative disorders and ageing; IRL1117, a drug candidate developed for once-daily oral treatment for the hallmark symptoms of Parkinson’s; and IRL757 to treat apathy in...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 34
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: IRLAB.A

Financial Performance

In 2023, HAKI Safety AB's revenue was 1.19 billion, an increase of 1.71% compared to the previous year's 1.17 billion. Earnings were 62.00 million, a decrease of -12.68%.